A while back, I wrote a post detailing my confused wonder at a proposed spin-off from Enzon of a biotech with all of the discovery engine. It turns out, I wasn’t the only one that was confused. In a letter, key Enzon shareholders wrote a letter demanding Enzon, “explore all setrategic alternatives for commercial operations.” In particular, they point to the ability of the company to reduce SG&A by at least $25M, (including, as I mentioned in the blog post, the ~5$M of CEO compensation):
“…the Company’s commercial operations generated over $80 million in adjusted EBITDA in 2007. It has long been our contention, however, that Enzon’s cost structure is inordinately high. Accordingly, we believe that there are at least $25 million of excess SG&A expenses that could be eliminated should the Company pursue a rationalization of its commercial operations. We note that the Company spent $31.9 million on selling and marketing expenses alone in its marketed products segment in 2007. As an additional data point, the following information detailing the Company’s five most highly-compensated executives was taken from page 21 of the Company’s 2008 Proxy Statement:
Name Principal Position Total 2007 Compensation
Jeffrey H. Buchalter Chairman, President, and CEO $5,181,117 Craig A. Tooman EVP, Finance and Chief Financial Officer $1,673,573 Ivan D. Horak, M.D. EVP, R&D and Chief Scientific Officer $1,820,115 Ralph del Campo EVP, Technical Operations $1,354,414 Paul S. Davit EVP, Human Resources $898,516
These compensation figures seem excessive when viewed in the context of a small-cap company that has a current market value of less than $400 million. Indeed, we believe that $25 million of potential cost reductions may be a conservative estimate.”
Glad to see I’m not the only person being critical of this plan of action. I salute you, Richard Mansouri, portfolio manager of DellaCamera Capital Management, LLC.
Theoretically Related Posts
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)